Nasal Delivery of Cannabis-derived Therapeutics
Company Founded Year
Company Number of Employees
NeuroPharmacology | NeuroBioTechnology
Biotechnology & Biopharmaceutical
Medical use (pharma, nerve damage rehabilitation, neurodiagnostics. inc. early diagnosis)
Biochemical: pharmacological drugs (Developing drugs)
Brainose Technologies has developed a nose-to-brain delivery system for cannabis-derived therapeutics for the treatment of central nervous system (CNS) indications. Brainose is currently developing a pharmaceutical-grade cannabinoid-based therapy with a focus on pain management for FDA and CE approval in the U.S. and Europe.
The companyâ€™s mission is to provide the huge population that benefits from cannabis-derived therapeutics with accessibility to these medications in a simple, safe, efficient, and friendly manner. Its products are designed to ensure precise and reproducible dose delivery.
Brainose was founded as a collaboration between Cann10, an accelerator focused on medical cannabis, and Nextar Chempharma Solutions, a veteran pharmaceutical company. Brainose has partnered with SipNose to further progress on its drug delivery platform.